[抗纤维化药物尼达尼布和吡非尼酮的随机临床试验进展]

[Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone].

作者信息

Li Y H, Ye Q

机构信息

Department of Occupational Medicine and Toxicology, Clinical Center for Interstitial Lung Diseases, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

出版信息

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2020 Jan 20;38(1):62-65. doi: 10.3760/cma.j.issn.1001-9391.2020.01.016.

DOI:10.3760/cma.j.issn.1001-9391.2020.01.016

PMID:32062902

Abstract

Pulmonary fibrosis is the terminal manifestation of a variety of interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF) is one of the chronic, progressive, fibrotic lung disease with high incidence and poor prognosis. Nintedanib and pirfenidone are currently marketed anti-pulmonary fibrosis drugs, and their efficacy and safety are recognized in patients with IPF. This article reviews the targets and clinical trials of the two drugs, and provides a basis for the expansion of indications for anti-pulmonary fibrosis drugs.

摘要

肺纤维化是多种间质性肺疾病的终末期表现。特发性肺纤维化（IPF）是一种慢性、进行性、纤维化的肺部疾病，发病率高且预后较差。尼达尼布和吡非尼酮是目前已上市的抗肺纤维化药物，它们在IPF患者中的疗效和安全性得到认可。本文综述了这两种药物的作用靶点和临床试验情况，为抗肺纤维化药物扩大适应证提供依据。